↓ Skip to main content

Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates

Overview of attention for article published in BMC Pharmacology and Toxicology, June 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 149)
  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
3 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
21 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
Published in
BMC Pharmacology and Toxicology, June 2015
DOI 10.1186/s40360-015-0018-9
Pubmed ID
Authors

Lisa Jamieson, William McCully

Abstract

Phthalates are excipients in drug formulations. However, concerns have been raised about the effects of particular phthalates on reproduction and development. As a result the EMA has introduced guidelines for permitted daily exposure (PDE) limits for certain phthalates. Therefore, the objective of this study was to identify UK licensed medicines that contain the relevant phthalates and determine if they fall within the recommended PDE. The eMC was used to identify which UK licensed medicines contain the phthalates in question. Companies were then contacted for information on the phthalate levels in their products, which was compared with the PDE recommended by the EMA. The eMC search revealed that 54 medicines contained at least one of the phthalates in question. However, only six medicines, namely Asacol 800 mg MR (Warner Chilcott UK), Epilim 200 Gastro-resistant tablets (Sanofi), Prednisolone 2.5 mg and 5 mg Gastro-resistant tablets (Actavis UK), Vivotif (Crucell Italy S.r.l), and Zentiva 200 mg Gastro-resistant tablets (Winthrop Pharmaceuticals UK), were identified as containing levels that exceeded the recommended PDE. These findings indicate that very few UK licensed medicines will be affected by the proposed EMA guidelines. For those medicines identified as exceeding recommendations, these findings highlight the need to instigate a risk-benefit review.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 29%
Researcher 3 14%
Student > Ph. D. Student 3 14%
Other 2 10%
Student > Postgraduate 2 10%
Other 1 5%
Unknown 4 19%
Readers by discipline Count As %
Medicine and Dentistry 9 43%
Pharmacology, Toxicology and Pharmaceutical Science 4 19%
Environmental Science 1 5%
Agricultural and Biological Sciences 1 5%
Arts and Humanities 1 5%
Other 0 0%
Unknown 5 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2015.
All research outputs
#1,209,271
of 5,234,236 outputs
Outputs from BMC Pharmacology and Toxicology
#48
of 149 outputs
Outputs of similar age
#52,304
of 178,106 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#2
of 6 outputs
Altmetric has tracked 5,234,236 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 149 research outputs from this source. They receive a mean Attention Score of 4.2. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 178,106 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.